New drug combo targets specific cancer marker in advanced tumors
NCT ID NCT07387081
Summary
This study is testing whether a new drug called LM-24C5, when combined with other cancer treatments, can help control advanced solid tumors that have a specific marker called CEACAM5. It will involve about 130 adults with advanced cancer that has returned or isn't responding to standard treatments. Researchers will measure how well the tumors shrink, how long the treatment works, and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
Contact
-
Shanghai East Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200123, China
Contact
Conditions
Explore the condition pages connected to this study.